TargetBeta
ADRA1A
adrenoceptor alpha 1A · also ADRA1L1, ADRA1C · Adrenoceptors
7 programs in company-led studies act on ADRA1A, from 6 companies: 1 in phase 3, 6 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (7 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Tamsulosinrule | Boehringer Ingelheim | phase 4 | 605 running | ADRA1B, ADRA1D | ChEMBL |
| Epinephrinerule | Nasus Pharma | phase 4 | 175 running | ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 | ChEMBL |
| Oxymetazolinerule | AbbVie | phase 4 | 201 running | ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C | ChEMBL |
| Phentolaminerule | Opus Genetics | phase 4 | 181 running | ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C | ChEMBL |
| silodosinrule | AbbVie | phase 4 | 170 running | – | ChEMBL |
| Midodrinerule | Takeda | phase 4 | 100 running | ADRA1B, ADRA1D | ChEMBL |
| Prazosinrule | Pfizer | phase 3 | 40 running | ADRA1B, ADRA1D | ChEMBL |
Conditions their studies are in
- Lower Urinary Tract Symptoms, 2 programs
- Prostatic Hyperplasia, 2 programs
- Alzheimer Disease, 1 program
- Anaphylaxis, 1 program
- Asthma, 1 program
- Chronic Urticaria, 1 program
- Erectile Dysfunction, 1 program
- Erythema, 1 program
- Fecal Incontinence, 1 program
- Glaucoma, Open-Angle, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 2027Epinephrine · Nasus Pharma · phase 4 · NCT06834165
- Aug 2027Phentolamine · Opus Genetics · phase 4 · NCT07140783
- Aug 31, 2027Tamsulosin · Boehringer Ingelheim · phase 4 · NCT07870759
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.